GenSight Biologics (SIGHT) H2 2024 earnings summary

Executive summary

• 2024 consolidated financial results confirmed in line with prior estimates, with annual net loss of €14.0 million and operating loss of €15.8 million.

• Cash position at year-end 2024 was €2.5 million, with additional €0.9 million equity financing and €1.1 million research tax credit expected.

• Going concern basis maintained, but substantial doubt exists due to funding shortfall beyond early May 2025.

Financial highlights

• Operating income for 2024 was €2.6 million, down from €3.0 million in 2023.

• Net loss improved to €14.0 million in 2024 from €26.2 million in 2023.

• Cash and cash equivalents increased to €2.5 million at year-end 2024 from €2.1 million in 2023.

• Total debt decreased to €37.7 million from €39.8 million year-over-year.

• Basic and diluted loss per share improved to €(0.15) from €(0.54) year-over-year.

Outlook and guidance

• Current funding expected to last until early May 2025; additional bridge financing and AAC program resumption targeted to extend runway.

• AAC program for LUMEVOQⓇ expected to resume in April 2025, with first payments anticipated to support operations.

• Additional debt, equity, or partnership/M&A required before H2 2026 to meet working capital and rebate obligations.